Tokyo, Japan –Aug. 15, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the closing of the Company's Seed Round Financing, adding $1.6 million in additional new equity. New venture capital investors NIF SMBC Ventures, Nikko AntFactory and Japan Asia Investment Company, joined existing shareholders.